Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclinical and phase 1 vaccine candidates to expand its respiratory syncytial virus (RSV) pipeline beyond mRNA.

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

In RSV, Sanofi is represented by Beyfortus, an FDA-approved antibody drug that works like a vaccine, providing infants and young children protection from the respiratory pathogen.

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season. Paris, June 9, 2025. Sanofi is shipping Beyfortus starting in early Q3 to ...

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was ...

Infant RSV hospitalisations fell 69 per cent in Spain during the 2024 to 2025 season compared with the 2022 to 2023 season, when immunisation therapies were unavailable. Rates decreased almost 27 ...

Sanofi noted that Beyfortus will be provided in hospital prior to discharge for babies born during RSV season and is available through primary care providers or public health in Quebec, Ontario ...

FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 3:15 pm ...

Weekly hospital admission rates for RSV have doubled over the past month among children. In the week ending November 18, there were about 23 hospitalizations for every 100,000 children under 5.

Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.

Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which typically starts in November ...

Sanofi on Monday revealed an aggressive effort to increase supply of Beyfortus, including a plan to begin shipping the shot early in the third quarter. Last year, Beyfortus booked sales of €1.7 ...